-- Three medical experts will join members of Syros' leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the opportunity for tamibarotene on Tuesday, June 25 at 11:00 a.m. ET --

-- Syros expects to report pivotal Phase 3 data from SELECT-MDS-1 by mid-4Q 2024 --

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday, June 25, 2024, from 11:00 a.m. – 12:30 p.m. ET.

Syros is currently evaluating tamibarotene in SELECT-MDS-1, a pivotal Phase 3 clinical trial in HR-MDS patients with RARA overexpression, and in SELECT-AML-1, a Phase 2 clinical trial in unfit acute myeloid leukemia (AML) patients with RARA overexpression. Syros expects to report pivotal complete response data from the SELECT-MDS-1 trial by the middle of the fourth quarter of 2024 and will report clinical activity and tolerability data from a prespecified analysis of over 40 patients from the SELECT-AML-1 trial in the third quarter of 2024.

The webcast event will feature presentations from Amy DeZern, M.D., M.H.S., Professor of Oncology and Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Amer Zeidan, M.B.B.S., M.H.S., Chief, Hematologic Malignancies, Yale Cancer Center and Smilow Cancer Hospital; Associate Professor of Medicine (Hematology), Yale School of Medicine and David Sallman, M.D., Myeloid Section Head and Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute. The speakers will provide a disease overview of HR-MDS, including current therapies and approach to patient management, evaluation of patient outcomes in HR-MDS trials, and the emerging treatment landscape and ongoing areas of unmet need. In addition, members of Syros' leadership team will provide an overview of RARA overexpression and tamibarotene's mechanism of action, review the design of the pivotal SELECT-MDS-1 Phase 3 trial, and discuss previously presented clinical data supporting the development of tamibarotene for HR-MDS and the potential commercial opportunity.

There will be an opportunity for Q&A during the presentation. Participants can register for the live webcast here. For participants joining via conference call, please dial (800) 549-8228 (domestic) or (646) 564-2877 (international) and refer to conference ID 68622. In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available following the presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Syros' clinical development plans, the progression of its clinical trials, the timing to report clinical data, the ability to deliver benefit to patients, and the commercial potential of tamibarotene. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "hope," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including Syros' ability to: advance the development of its programs under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug candidates; successfully develop a companion diagnostic test to identify patients with the RARA biomarker; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described under the caption "Risk Factors" in Syros' Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, each of which is on file with the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange Commission in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613264695/en/